DexCom, Inc. Share Price and Company Fundamentals
Last traded: Last Wednesday at 8:00 PM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
|Industry / Sector||Diagnostics & Research / Healthcare|
|Full time employees||5500|
|Mailing address||6340 Sequence Drive San Diego CA 92121 United States|
|Phone / Fax||858 200 0200 /|
DexCom, Inc. does not pay dividends.
As of May 2021, following are the company executives and directors listed on DexCom, Inc..
|Mr. Kevin Ronald Sayer||Exec. Chairman, CEO & Pres||62||2.63M|
|Mr. Quentin S. Blackford||Chief Operating Officer||41||1.48M|
|Mr. Jacob Steven Leach||Exec. VP & CTO||42||1M|
|Mr. Jereme M. Sylvain||Exec. VP, CFO & Chief Accounting Officer||40|
|Mr. Sean Christensen||Director of Corp. Affairs & Head of Investor Relations|
|Mr. Patrick Michael Murphy||Exec. VP & Chief Legal Officer||41|
|Mr. Chad M. Patterson||Exec. VP of Global Marketing||38|
|Ms. Sadie M. Stern||Exec. VP & Chief HR Officer||45|
|Mr. Andrew K. Balo||Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel.||72|
|Mr. Steven R. Pacelli||Exec. VP & MD of Dexcom Ventures||48|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of DexCom, Inc. is 32.25B and its enterprise value is 35.16B. The enterprise value to revenue ratio of DXCM is 17.35.
The DXCM's stocks Beta value is 0.75 making it 25% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
DexCom, Inc. (NASDAQ:DXCM) Frequently Asked Questions
1. What is DexCom, Inc.'s Stock Symbol?
DexCom, Inc. trades on NASDAQ under the ticker symbol "DXCM".
2. What is DexCom, Inc.'s stock price today?
One share of DXCM stock can currently be purchased for approximately $333.48.
3. How can I contact DexCom, Inc.?
DexCom, Inc.'s mailing address is 6340 Sequence Drive San Diego CA 92121 United States. The company can be reached via phone at 858 200 0200.
4. What is DexCom, Inc.'s official website?
The official website of DexCom, Inc. is http://www.dexcom.com.